Buy, Sell or Hold: Citi upgrades Dr Lal Pathlabs; raises target price for healthcare stock – Markets
Buy, Sell or Hold: Global brokerage firm Citi has upgraded Dr Lal PathLabs to a “Buy” rating, signifying a positive outlook for the diagnostic major in the medium term. At the same time, Citi has upgraded the target price for the stock to Rs 1650 from Rs 1450. According to the brokerage, the organic revenue…
